El interés en corto de WORK Medical Tech Gr da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de WORK Medical Tech Gr. Los datos de interés en corto se actualizan cada dos semanas.

WORK Medical Tech Gr (NASDAQ:WOK) Bolsa, Informe de interés en corto

WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.

WORK Medical Technology Group LTD - Class A Ordinary Shares

WORK Medical Technology Group Ltd

News

Insider Trades

Live On CNBC, Sarat Sethi Announces Sold APA

WIIM

TEAM

Atlassian shares are trading higher after Stephens & Co initiated coverage on the stock with an Equal-Weight rating and announced a $255 price target.

Wednesday, Immunovant,&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic inflammatory <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">demyelinating polyneuropathy (CIDP)</a>.
Immunovant is a member of the&nbsp;Roivant Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) family of companies.
In the Phase 3 MG study, batoclimab met its primary endpoint of mean change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44395056/immunovant-announces-positive-results-for-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory" rel="noreferrer noopener">antibody positive (AChR+) participants</a>.
<ul>
<li>Participants entering the study and randomized to 680mg of batoclimab given weekly by subcutaneous injection achieved a 5.6-point improvement (with 74% mean IgG reduction) in MG-ADL at Week 12.</li>
<li>In comparison, those randomized to 340mg of batoclimab given weekly by subcutaneous injection achieved a 4.7-point improvement (with 64% mean IgG reduction).</li>
<li>Those randomized to placebo experienced a 3.6-point improvement in MG-ADL at Week 12.</li>
</ul>
Initial batoclimab data in 73 patients pooled across all cohorts for the run-in Period 1 of the Phase 2b CIDP study demonstrated a 1.8 point improvement in aINCAT (compared to Period 1 baseline) at Week 12.
<ul>
<li>An 84% responder rate (with response defined as an aINCAT improvement ≥ 1) was observed among all patients whose IgG was reduced by ≥ 70%.</li>
<li>Other CIDP scales also demonstrated meaningful improvements for pooled batoclimab cohorts, with an improvement in I-RODS of 15.3, an improvement in MRC-SS of 5.6, and an improvement in grip strength of 15.1.</li>
</ul>
Safety and tolerability were observed to be consistent with prior batoclimab studies.
Immunovant does not intend to seek regulatory approval for batoclimab in MG or CIDP and is focused on leveraging data and learnings from the batoclimab studies to accelerate programs with IMVT-1402.
Immunovant plans to initiate potentially registrational studies in MG and CIDP with lead asset IMVT-1402 and has received clearance for its Investigational New Drug applications.
Immunovant will wait to decide on regulatory submissions for batoclimab until the results of the ongoing Phase 3 studies of batoclimab in thyroid eye disease are available.
Price Action: IMVT stock is down 0.40% at $18.72 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/03/44396557/spectral-ai-deepview-system-performs-plans-product-launch-in-2026" target="_blank" rel="noreferrer noopener">Spectral AI DeepView System Performs, Plans Product Launch In 2026</a></li>
</ul>

Biotech

Health Care

General

IMVT

ROIV

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

Regenxbio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) revealed on Wednesday new interim data from two additional patients in the Phase 1/2 portion of the AFFINITY DUCHENNE trial of RGX-202, an investigational gene therapy for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne muscular dystrophy</a>.
Results were presented at the 2025 Muscular Dystrophy Association (MDA) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44397327/regenxbio-reports-positive-biomarker-data-from-affinity-duchenne-trial-of-rgx-202-gene-therapy" rel="noreferrer noopener">Clinical &amp; Scientific Conference</a>.
At dosing, microdystrophin expression was 122.3% higher in a patient age three compared to the control.
In a patient age seven, RGX-202 microdystrophin expression was 31.5% higher than in the control.
In all patients, RGX-202 was appropriately localized to the sarcolemma, demonstrating the differentiated construct with the CT-Domain is appropriately targeting the muscle.
RGX-202 microdystrophin expression results in ambulatory patients age eight and above are the highest reported microdystrophin levels across approved or investigational gene therapies.
To support a Biologics License Application (BLA) using the accelerated approval pathway, the primary endpoint in the pivotal phase of AFFINITY DUCHENNE is the proportion of participants whose RGX-202 microdystrophin expression is ≥10% at Week 12.
RGX-202 also demonstrates the highest reported vector genome copies (4.9-55.4) measured by qPCR across approved or investigational gene therapies.
As of Feb. 21, 2025, RGX-202 was well tolerated, with no serious adverse events or AEs of special interest. Common drug-related AEs included nausea, vomiting and fatigue. All were resolved and typically anticipated with gene therapy administration.
Phase 3 portion of the AFFINITY DUCHENNE trial is enrolling ambulatory patients (who can walk) aged one and above, on track for BLA submission in mid-2026.
Last week, Regenxbio reported a fourth-quarter loss of $1.01 per share, beating the consensus of $1.15.
Sales decreased slightly from $22.2 million to $21.21 million, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $23.75 million</a>.
Regenxbio expects its cash, cash equivalents and marketable securities of $244.9 million as of Dec. 31, 2024, and the $110 million upfront payment to be received under the Nippon Shinyaku collaboration to fund its operations into the <a href="https://www.benzinga.com/pressreleases/25/03/n44315595/regenxbio-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-operational-updat" target="_blank" rel="noreferrer noopener">second half of 2026</a>.
RGNX Price Action: Regenxbio stock is up 5.90% at $8.26 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44394817/exclusive-telomir-pharmaceuticals-lead-drug-candidate-inhibits-tumor-growth-in-aggressive-prostate-cancer-cells-animal-study-shows" target="_blank" rel="noreferrer noopener">Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows</a></li>
</ul>

Movers

RGNX

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial

On Wednesday, Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) announced the pricing of its underwritten registered offering, which includes 46.5 million shares of common stock and pre-funded warrants to purchase approximately 139 million shares, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44397534/plug-power-inc-announces-pricing-of-upsized-280-million-underwritten-offering" rel="noreferrer noopener">totaling 185.4 million common stock equivalents.</a>
The common stock equivalents will be accompanied by a total of 185.4 million warrants. The gross proceeds from this offering are expected to be about $280 million, before deducting underwriting fees and other expenses.
Each common stock share and accompanying warrant are being sold at a combined price of $1.51, while pre-funded warrants are priced at $1.509 with an exercise price of $0.001 per share.
The warrants have an exercise price of $2.00 per share and will become exercisable six months after issuance. Plug Power intends to use the net proceeds for working capital and general corporate purposes.
Also Read: <a target="_blank" href="http://benzinga.com/analyst-ratings/analyst-color/25/03/44399554/analysts-see-upside-for-95-of-sp-500-stocks-how-nvidia-tesla-stack-up" rel="noreferrer noopener">Analysts See Upside For 95% Of S&amp;P 500 Stocks: How Nvidia, Tesla Stack Up</a>
CEO Andy Marsh expressed that the funding would strengthen the company's financial position and help drive profitability in 2025.
The funds will support the company's initiatives to optimize operations, improve cash flow, and focus on sustainable growth. The offering is expected to close on or about March 20, 2025, subject to customary closing conditions.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PLUG stock has lost over 50% in the past year. Investors can gain exposure to the stock via Global X Hydrogen ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYDR#NASDAQ">HYDR</a>) and&nbsp;ETF Series Solutions Defiance Next Gen H2 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDRO#NYSE">HDRO</a>).
Recently, the company reported fourth-quarter revenue of&nbsp;$191.5 million, missing&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst&nbsp;estimates&nbsp;of&nbsp;$263.2 million</a>.
The company reached a pivotal milestone in electrolyzer deployments, expanded its hydrogen network, and enhanced the utilization of its manufacturing facilities.
Price Action: PLUG shares are trading lower by 0.93% to $1.605 at last check Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44401134/hutchmeds-oncology-revenue-hits-271-5-million-rising-65-on-fruzaqla-strength" target="_blank" rel="noreferrer noopener">Hutchmed&#8217;s Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength</a></li>
</ul>
Photo via Shutterstock.

Equities

Offerings

Markets

ETF Series Solutions Defiance Next Gen H2 ETF

HDRO

HYDR

PLUG

What's Going On With Plug Power Stock Today?

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and raises the price target from $70 to $76.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on National Health Investors, Raises Price Target to $76

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) with a Buy and maintains $51 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $51 Price Target

Morgan Stanley analyst Andrew Tsai maintains KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) with a Overweight and raises the price target from $19 to $27.

BEKE

Morgan Stanley Maintains Overweight on KE Holdings, Raises Price Target to $27

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and maintains $10 price target.

ATAI

HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $10 Price Target

United Rentals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) short percent of float has risen 4.45% since its last report. The company recently reported that it has 1.75 million shares sold short, which is 3.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>United Rentals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742401826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for United Rentals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing United Rentals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, United Rentals's peer group average for short interest as a percentage of float is 4.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About United Rentals?

Toyota Motor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 921 thousand shares sold short, which is 0.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Toyota Motor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742401820_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Toyota Motor has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Toyota Motor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Toyota Motor's peer group average for short interest as a percentage of float is 5.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Toyota Motor?

Nu Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) short percent of float has risen 13.04% since its last report. The company recently reported that it has 136.00 million shares sold short, which is 3.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Nu Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742401815_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nu Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Nu Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Nu Holdings's peer group average for short interest as a percentage of float is 1.03%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Nu Holdings?

Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares are trading higher today.
On Wednesday, the company renewed its partnership with Churchill Downs Racetrack as the exclusive automotive partner of the Kentucky <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44398200/ford-named-exclusive-automotive-partner-of-the-kentucky-derby-in-multi-year-partnership-extension" rel="noreferrer noopener">Derby presented by Woodford Reserve</a>.
Under the multi-year deal extending through 2029, Ford will expand its presence at Churchill Downs by securing naming rights to the First Turn Club, now officially the Ford First Turn Club.
This extended collaboration grants Ford category exclusivity and an expanded presence with interactive vehicle displays to enhance fan engagement during Derby Week and beyond.
Related Read: <a target="_blank" href="https://www.benzinga.com//node/44390358" rel="noreferrer noopener">Elon Musk Calls It &#8216;Extreme Domestic Terrorism&#8217; After Website Publishes Data On US Tesla Owners</a>
Additionally, Ford will showcase exclusive luxury vehicle displays and new Ford-themed fan experiences at key locations, including the Paddock Plaza and VIP Gate, ensuring strong brand visibility throughout Derby Week.
Ford will continue its sponsorship of key Kentucky Derby and Oaks activations, including branding on the Derby Starting Gate, presenting sponsorship of the Churchill Downs Barn Area, a Derby Day race entitlement, exclusive digital content, and year-round vehicle displays at Churchill Downs.
Phil O&#8217;Connor, director of global marketing communications – Ford Blue and Model e at Ford Motor Company said, &#8220;Ford&nbsp;has a deep connection with the&nbsp;Louisville&nbsp;community. Our&nbsp;Louisville-based manufacturing facilities employ roughly 12,000 Kentuckians.&#8221;
&#8221;Our heritage of capability, passion and innovation make our friends at Churchill Downs Racetrack ideal partners. We&#8217;re excited for this next chapter in our partnership and honored to continue supporting the bluegrass state.&#8221;
Earlier this month, Ford Pro partnered with Work Truck Solutions to introduce an online tool that helps customers easily find road- and work-ready trucks <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44149002/work-truck-solutions-announces-collaboration-with-ford-pro-to-power-commercial-vehicle-locator" rel="noreferrer noopener">and vans in Ford dealer inventory</a>.
Investors can gain exposure to the stock via&nbsp;First Trust Nasdaq Transportation ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXR#NASDAQ">FTXR</a>).
Price Action: F shares are up 0.91% at $10.05 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/03/44262286/tariff-uncertainty-poses-major-risk-to-us-automakers-how-much-could-ford-gm-earnings-fall" target="_blank" rel="noreferrer noopener">Tariff Uncertainty Poses Major Risk To US Automakers: How Much Could Ford, GM Earnings Fall?</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Contracts

FTXR

Ford Renews Exclusive Partnership with Kentucky Derby, Expands Brand Presence Through 2029

INTC

Intel shares are trading lower, pulling back after gaining recently on new CEO optimism.

NVDA

NVIDIA shares are trading higher amid the company's GTC Conference this week.

GILD

Gilead Sciences shares are trading lower after reports indicating the Trump administration is considering cuts to domestic HIV prevention programs.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) with a Buy and maintains $60 price target.

DTIL

HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) with a Buy and raises the price target from $12 to $15.

FEMY

HC Wainwright & Co. Maintains Buy on Femasys, Raises Price Target to $15

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) near-term trajectory and dynamic regarding Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) will depend on technical indicators and the outcome of Wednesday&#8217;s Federal Open Market Committee decision, according to <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44377385/bitcoin-remains-stuck-in-the-low-80000s-what-does-technical-analysis-say">prominent analyst Benjamin Cowen</a>.
What Happened: In a <a href="https://www.youtube.com/watch?v=T8BQXl7PcJ4">podcast</a> published on Tuesday, Cowen identified Bitcoin&#8217;s weekly Relative Strength Index (RSI) support level having hit the 44 level for the third time in this cycle, after previous touches in September 2023 and September 2024.
If BTC holds this level, it would align with the 2016-2017 bull cycle. 
A break below 44 RSI, however, could mean the market resembles 2019-2020's choppier period instead.
Cowen noted that while 2016-2017 had risk-on periods in February, this cycle has remained risk-off through January, February and March, raising concerns about market strength.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44398922/the-bitcoin-fomc-preview-a-dovish-powell-pivot-could-send-btc-to-90000">The Bitcoin FOMC Preview: A Dovish Powell Pivot Could Send BTC To $90,000</a>
What's Next: In another <a href="https://www.youtube.com/watch?v=UdtpOP_uBc0">podcast</a>, Cowen examined the impact of Federal Reserve policy on crypto markets, particularly Ethereum.
He commented on the Federal Reserve's upcoming policy decision, suggesting the continuation of quantitative tightening has significantly impacted market dynamics, particularly for altcoins.
The last time ETH was at ~$1,800 (2022), Bitcoin traded around $20,000-$25,000. 
Now, Bitcoin is nearly 4x higher, but ETH has remained at the same price, indicating altcoins are lagging BTC significantly.
Looking ahead to the FOMC meeting, Cowen noted that if quantitative tightening ends, historical patterns suggest ETH/BTC would bounce, similar to previous cycles.
Inflation concerns could delay a Fed pivot, making a rapid recovery uncertain. 
&#8220;They might not be as willing to support markets in the same way as quickly until it&#8217;s more apparent that inflation is actually coming back down to earth,&#8221; Cowen said.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44383822/bitcoin-drops-16-in-a-month-are-bear-market-signals-flashing">Bitcoin Drops 16% In A Month: Are Bear Market Signals Flashing?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Bitcoin, Ethereum Face Uncertain Future: What Do Technical Indicators Say?

CAAP

Corporacion America Airports shares are trading lower after the company reported a Q4 GAAP EPS miss.

Press Releases

WORK Medical Technology Group LTD Announces Pricing of Initial Public Offering

Kingswood Capital Partners, LLC Announces Pricing of $8 Million Initial Public Offering of Ordinary Shares for its Client WORK Medical Technology Group LTD. (Nasdaq: WOK)

Comments

WORK Medical Tech Gr

Interés en corto

WORK Medical Tech Gr (NASDAQ:WOK) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL